Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Antiplatelet Therapy in Acute Coronary Syndromes. Lights and Shadows of Platelet Function Tests to Guide the Best Therapeutic Approach

Author(s): Giovanni Cimmino, Emanuele Gallinoro, Luigi Di Serafino, Nicola De Luca and Plinio Cirillo*

Volume 18, Issue 3, 2020

Page: [262 - 272] Pages: 11

DOI: 10.2174/1570161117666190513105859

Price: $65

Abstract

The key role of platelets in pathophysiology of Acute Coronary Syndromes (ACS) has been well recognized. Platelet activation and aggregation, together with tissue factor-pathway activation, lead to acute thrombus formation in the coronary vessels at sites of plaque rupture. Thus, antiplatelet therapy with drugs able to interfere with platelet activation/aggregation represents a cornerstone of ACS treatment in intensive care units and catheterisation labs. Several observational studies have described that residual high platelet reactivity, despite antiplatelet therapy, is associated with increased risk of nonfatal Myocardial Infarction (MI), definite/probable stent thrombosis and cardiovascular mortality. Thus, assessment of platelet function with reliable and reproducible platelet function tests might be crucial to identify patients at high risk of thrombosis or not responding to ongoing antiplatelet strategies. However, despite this promising background, some randomized clinical trials have failed to demonstrate improvement in outcomes when using platelet function tests for clinical decision-making. This review, after describing platelet biology and pathophysiology of ACS, briefly considers the drugs currently approved for use in patients with ACS or treated by the percutaneous coronary intervention (PCI). Finally, we provide an updated overview of the current methods to evaluate platelet reactivity in the clinical setting of ACS illustrating their potential advantages/limitations in current clinical practice.

Keywords: Acute coronary syndromes, platelet, platelet function tests, thrombosis, antiplatelet therapy, therapeutic approach.

« Previous Next »
Graphical Abstract

[1]
Cimmino G, Tarallo R, Conte S, et al. Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul Pharmacol 2018; 111: 62-70.
[http://dx.doi.org/10.1016/j.vph.2018.09.004] [PMID: 30287213]
[2]
Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. ScientificWorldJournal 2014; 2014 781857
[http://dx.doi.org/10.1155/2014/781857] [PMID: 24729754]
[3]
Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31(4): 381-92.
[http://dx.doi.org/10.1055/s-2005-916671] [PMID: 16149014]
[4]
Cimmino G, Fischetti S, Golino P. The two faces of thrombosis: Coagulation cascade and platelet aggregation. Are platelets the main therapeutic target? J Thrombo Cir: Open Access 2017; 3.
[http://dx.doi.org/10.4172/2572-9462-3-117]
[5]
Cimmino G, Ciccarelli G, Golino P. Role of tissue factor in the coagulation network. Semin Thromb Hemost 2015; 41(7): 708-17.
[http://dx.doi.org/10.1055/s-0035-1564045] [PMID: 26408920]
[6]
Cimmino G, Golino P. Platelet biology and receptor pathways. J Cardiovasc Transl Res 2013; 6(3): 299-309.
[http://dx.doi.org/10.1007/s12265-012-9445-9] [PMID: 23307175]
[7]
Atalar E, Aytemir K, Haznedaroğlu I, et al. Platelet and leukocyte deactivation after intracoronary stent placement in patients receiving combined antiplatelet therapy. Clin Appl Thromb Hemost 2001; 7(2): 116-21.
[http://dx.doi.org/10.1177/107602960100700207] [PMID: 11292188]
[8]
Stakos DA, Tziakas DN, Stellos K. Mechanisms of platelet activation in acute coronary syndromes. Curr Vasc Pharmacol 2012; 10(5): 578-88.
[http://dx.doi.org/10.2174/157016112801784477] [PMID: 22338573]
[9]
Michelson AD. Platelets. 3rd ed. Amsterdam: Academic Press 2013; pp. 1353-5.
[10]
Gremmel T, Frelinger AL III, Michelson AD. Platelet Physiology. Semin Thromb Hemost 2016; 42(3): 191-204.
[http://dx.doi.org/10.1055/s-0035-1564835] [PMID: 26926581]
[11]
Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet activation: The mechanisms and potential biomarkers. BioMed Res Int 2016; 2016 9060143
[http://dx.doi.org/10.1155/2016/9060143] [PMID: 27403440]
[12]
Rumbaut RE, Thiagarajan P. Platelet-vessel wall interactions in hemostasis and thrombosis. San Rafael, CA: Morgan & Claypool Life Sciences 2010.
[http://dx.doi.org/10.4199/C00007ED1V01Y201002ISP004]
[13]
Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018; 2(3): 439-49.
[http://dx.doi.org/10.1002/rth2.12115] [PMID: 30046748]
[14]
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119-77.
[http://dx.doi.org/10.1093/eurheartj/ehx393] [PMID: 28886621]
[15]
Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121(1): 171-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.853069] [PMID: 20048234]
[16]
Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40(2): 87-165.
[http://dx.doi.org/10.1093/eurheartj/ehy394] [PMID: 30165437]
[17]
Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 esc guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European stroke organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (esc) and of the European society for vascular surgery (ESVS). Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[18]
Hashemzadeh M, Furukawa M, Goldsberry S, Movahed MR. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review. Exp Clin Cardiol 2008; 13(4): 192-7.
[PMID: 19343166]
[19]
Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015; 11: 133-48.
[http://dx.doi.org/10.2147/VHRM.S44469] [PMID: 25733843]
[20]
Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123(2): 172-83.
[http://dx.doi.org/10.1309/Y9EC63RW3XG1V313] [PMID: 15842039]
[21]
Femia EA, Pugliano M, Podda G, Cattaneo M. Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry. Platelets 2012; 23(1): 7-10.
[http://dx.doi.org/10.3109/09537104.2011.596592] [PMID: 21770862]
[22]
Hayward CP, Moffat KA, Raby A, et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134(6): 955-63.
[http://dx.doi.org/10.1309/AJCP9V3RRVNZMKDS] [PMID: 21088160]
[23]
Hvas AM, Favaloro EJ. Platelet function analyzed by light transmission aggregometry. Methods Mol Biol 2017; 1646: 321-31.
[http://dx.doi.org/10.1007/978-1-4939-7196-1_25] [PMID: 28804839]
[24]
Lordkipanidzé M. Platelet function tests. Semin Thromb Hemost 2016; 42(3): 258-67.
[http://dx.doi.org/10.1055/s-0035-1564834] [PMID: 26926583]
[25]
Hayward CP. Diagnostic approach to platelet function disorders. Transfus Apheresis Sci 2008; 38(1): 65-76.
[http://dx.doi.org/10.1016/j.transci.2007.12.009] [PMID: 18291723]
[26]
Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 2002; 126(2): 133-46.
[PMID: 11825107]
[27]
Choi JL, Li S, Han JY. Platelet function tests: a review of progresses in clinical application. BioMed Res Int 2014; 2014 456569
[http://dx.doi.org/10.1155/2014/456569] [PMID: 24895576]
[28]
Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62(24): 2261-73.
[http://dx.doi.org/10.1016/j.jacc.2013.07.101] [PMID: 24076493]
[29]
Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3(2): 135-58.
[http://dx.doi.org/10.1016/0160-5402(80)90024-8] [PMID: 7392654]
[30]
Jagroop IA, Mikhailidis DP. The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation. Clin Appl Thromb Hemost 2008; 14(3): 295-302.
[http://dx.doi.org/10.1177/1076029608316014] [PMID: 18445610]
[31]
Fritsma GA, McGlasson DL. Whole blood platelet aggregometry. Method Mol Biol 2017; 1646: 333-47.
[http://dx.doi.org/10.1007/978-1-4939-7196-1_26] [PMID: 28804840]
[32]
Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96(6): 781-8.
[PMID: 17139373]
[33]
Würtz M, Hvas AM, Christensen KH, Rubak P, Kristensen SD, Grove EL. Rapid evaluation of platelet function using the Multiplate® Analyzer. Platelets 2014; 25(8): 628-33.
[http://dx.doi.org/10.3109/09537104.2013.849804] [PMID: 24246241]
[34]
Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99(5): 620-5.
[http://dx.doi.org/10.1161/01.CIR.99.5.620] [PMID: 9950658]
[35]
Nielsen HL, Kristensen SD, Thygesen SS, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 2008; 123(2): 267-73.
[http://dx.doi.org/10.1016/j.thromres.2008.03.023] [PMID: 18499236]
[36]
Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J 2012; 164(1): 35-42.
[http://dx.doi.org/10.1016/j.ahj.2012.03.022] [PMID: 22795280]
[37]
Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35(4): 209-15.
[http://dx.doi.org/10.1093/eurheartj/eht375] [PMID: 24067509]
[38]
Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21(Suppl. 2): 106-12.
[http://dx.doi.org/10.1055/s-0032-1313612] [PMID: 7660150]
[39]
Favaloro EJ. Clinical utility of closure times using the platelet function analyzer-100/200. Am J Hematol 2017; 92(4): 398-404.
[http://dx.doi.org/10.1002/ajh.24620] [PMID: 27935090]
[40]
Carubbi C, Masselli E, Gesi M, et al. Cytofluorimetric platelet analysis. Semin Thromb Hemost 2014; 40(1): 88-98.
[PMID: 24381148]
[41]
Linden MD. Platelet flow cytometry. Method Mol Biol 2013; 992: 241-62.
[http://dx.doi.org/10.1007/978-1-62703-339-8_18] [PMID: 23546718]
[42]
Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27(2): 81-90.
[http://dx.doi.org/10.1111/j.1365-2257.2005.00681.x] [PMID: 15784122]
[43]
Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2017; 72(4): 519-31.
[http://dx.doi.org/10.1111/anae.13765] [PMID: 28052313]
[44]
Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990; 81(1): I12-5.
[PMID: 2136814]
[45]
Fitzpatrick FA, Gorman RR, Mc Guire JC, Kelly RC, Wynalda MA, Sun FF. A radioimmunoassay for thromboxane B2. Anal Biochem 1977; 82(1): 1-7.
[http://dx.doi.org/10.1016/0003-2697(77)90127-0] [PMID: 907115]
[46]
Fitzpatrick FA, Gorman RR, Wynalda MA. Electron capture gas chromatographic detection of thromboxane B2. Prostaglandins 1977; 13(2): 201-8.
[http://dx.doi.org/10.1016/0090-6980(77)90001-6] [PMID: 847227]
[47]
Kumlin M, Granström E. Radioimmunoassay for 11-dehydro-TXB2: a method for monitoring thromboxane production in vivo. Prostaglandins 1986; 32(5): 741-67.
[http://dx.doi.org/10.1016/0090-6980(86)90196-6] [PMID: 3823488]
[48]
Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103(6): 1245-53.
[http://dx.doi.org/10.1160/TH09-08-0527] [PMID: 20352155]
[49]
Machin SJ, Briggs C. Mean platelet volume: a quick, easy determinant of thrombotic risk? J Thromb Haemost 2010; 8(1): 146-7.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03673.x] [PMID: 19874471]
[50]
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17(1): 47-58.
[http://dx.doi.org/10.2174/138161211795049804] [PMID: 21247392]
[51]
Jakl M, Sevcik R, Ceral J, Fatorova I, Horacek JM, Vojacek J. Mean platelet volume and platelet count: overlooked markers of high on treatment platelet reactivity and worse outcome in patients with acute coronary syndrome. Anadolu Kardiyol Derg 2014; 14(1): 85-6.
[PMID: 24342006]
[52]
Li W, Xie X, Wei D, et al. Baseline platelet parameters for predicting early platelet response and clinical outcomes in patients with non-cardioembolic ischemic stroke treated with clopidogrel. Oncotarget 2017; 8(55): 93771-84.
[http://dx.doi.org/10.18632/oncotarget.21622] [PMID: 29212188]
[53]
Quan W, Chen Z, Yang X, et al. Mean platelet volume/platelet count ratio as a predictor of 90-day outcome in large artery atherosclerosis stroke patients. Int J Neurosci 2017; 127(11): 1019-27.
[http://dx.doi.org/10.1080/00207454.2017.1296438] [PMID: 28270030]
[54]
Barradas MA, O’Donoghue S, Mikhailidis DP. Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo 1992; 6(6): 629-34.
[PMID: 1296813]
[55]
Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124(10): 1132-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.029165] [PMID: 21875913]
[56]
Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59(24): 2159-64.
[http://dx.doi.org/10.1016/j.jacc.2012.02.026] [PMID: 22520250]
[57]
Collet JP, Cayla G, Cuisset T, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011; 161: 5-12.
[58]
Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388(10055): 2015-22.
[http://dx.doi.org/10.1016/S0140-6736(16)31323-X] [PMID: 27581531]
[59]
Collet JP, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367(22): 2100-9.
[http://dx.doi.org/10.1056/NEJMoa1209979] [PMID: 23121439]
[60]
Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019; 55(1): 4-90.
[http://dx.doi.org/10.1093/ejcts/ezy289] [PMID: 30165632]
[61]
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2016; 152(5): 1243-75.
[http://dx.doi.org/10.1016/j.jtcvs.2016.07.044] [PMID: 27751237]
[62]
Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390(10104): 1747-57.
[http://dx.doi.org/10.1016/S0140-6736(17)32155-4] [PMID: 28855078]
[63]
Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56(24): 1994-2002.
[http://dx.doi.org/10.1016/j.jacc.2010.03.108] [PMID: 21126640]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy